Press releases
- NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
- NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
- NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
- NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
- NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
- NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
- NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
- NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
More ▼
Key statistics
As of last trade, NovaBay Pharmaceuticals Inc (B9P:DUS) traded at 0.076, 23.58% above the 52 week low of 0.0615 set on Apr 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.081 |
---|---|
High | 0.081 |
Low | 0.0715 |
Bid | 0.0775 |
Offer | 0.0835 |
Previous close | 0.081 |
Average volume | 0.00 |
---|---|
Shares outstanding | 36.06m |
Free float | 36.05m |
P/E (TTM) | -- |
Market cap | 3.28m USD |
EPS (TTM) | -3.82 USD |
Data delayed at least 15 minutes, as of May 07 2024 18:32 BST.
More ▼